These findings suggest that the dynamic alterations of lysoPCs may potentially be associated with the pharmacological actions of GLP-1 receptor signaling by dulaglutide and liraglutide on glucose metabolism and lipid handling in T2D patients. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.